Author Archives: admin


Stem Cell Clinic > Articles by: admin

Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer

By Global News Feed

SOUTH SAN FRANCISCO, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the appointment of Timothy Moore to Executive Vice President, Chief Technical Officer effective April 24, 2023. The selection of Mr. Moore, the former Executive Vice President, Technical Operations of Kite Pharma responsible for the global development of two of the most commercially successful autologous CAR T manufacturing processes in the industry, reinforces the Company’s mission to being the first to bring an AlloCAR T product to market. Mr. Moore succeeds Alison Moore, Ph.D., who intends to serve as a consultant to Allogene.

Excerpt from:
Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer

Codexis to Report First Quarter 2023 Financial Results on May 4

By Global News Feed

REDWOOD CITY, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2023 on Thursday, May 4, 2023, following the close of market. The Company will not be conducting a conference call in conjunction with this financial results release.

Continued here:
Codexis to Report First Quarter 2023 Financial Results on May 4

Elucida Oncology Announces Positive Early Phase 1 Safety Data Along with Preclinical Data for the Treatment of Brain Metastases for ELU001, an…

By Global News Feed

MONMOUTH JUNCTION, N.J., April 20, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, presented positive initial safety data from Phase 1 dose escalation trial of ELU001 (NCT05001282) in a poster titled “ELU-FR?-1: A Study to Evaluate ELU001, a C’Dot Drug Conjugate, in Patients with Solid Tumors that Overexpress Folate Receptor Alpha (FR?)” (abstract #CT255) at the American Association for Cancer Research (AACR) 2023 Annual Meeting. In addition, the company presented new preclinical data in a poster titled “Preclinical development of ELU001 - a folate receptor alpha (FR?)-targeted C’Dot drug conjugate (CDC) for the treatment of brain metastases” (abstract #837).

Read the original post:
Elucida Oncology Announces Positive Early Phase 1 Safety Data Along with Preclinical Data for the Treatment of Brain Metastases for ELU001, an...

Sirona Biochem Announces Close of Oversubscribed Debenture Financing

By Global News Feed

VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt: ZSB) (Xetra: ZSB) (the “Company”) announced today that it has closed an oversubscribed, non-brokered convertible debenture for gross proceeds of $1,563,600. The private placement consists of 1,563 Debenture units, (the “Debenture Units”) at a price of $1,000 per Debenture Unit.

Originally posted here:
Sirona Biochem Announces Close of Oversubscribed Debenture Financing

Biora Therapeutics to Participate in Crohn’s & Colitis Foundation’s IBD Innovate Conference

By Global News Feed

SAN DIEGO, April 20, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will participate in IBD Innovate: Product Development for Crohn’s & Colitis, an event hosted by the Crohn’s & Colitis Foundation to showcase innovative product development programs in inflammatory bowel disease (IBD), which will take place in New York City on April 26, 2023.

Read more from the original source:
Biora Therapeutics to Participate in Crohn’s & Colitis Foundation’s IBD Innovate Conference

→←